Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Change lives in myelofibrosis with JAKAVI1–3

JAKAVI (ruxolitinib) is the only licensed oral JAK1 and JAK2 inhibitor targeted therapy approved to treat adult patients with myelofibrosis (MF).1

 

JAKAVI (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis.1

 

Jakavi (ruxolitinib) logo
 

Abbreviations

MF, myelofibrosis.

References

  1. Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.
  2. Verstovsek S, et al. N Engl J Med. 2012;366:799–807.
  3. Harrison C, et al. N Engl J Med. 2012;366:787–798.
HCP20-C024 June 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]